Study of abbreviated antiplatelet therapy for patients at high risk for bleeding after undergoing percutaneous coronary intervention SAN FRANCISCO and MARLBOROUGH, Mass., Sept. 26, 2019 /PRNewswire/ — Boston Scientific (NYSE: BSX) has announced primary endpoint results from the EVOLVE Short DAPT clinical trial, the first prospective study initiated in the U.S. to examine the safety […]
Other News
Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan
CALGARY, Alberta, Sept. 27, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) today announces that it has issued a 10% secured convertible debenture in the principal amount of US$12 million (the “Debenture”) to a wholly-owned subsidiary of ORI Star Fund LP (“ORI” or the “Fund”). The […]
Resolute Onyx™ DES Meets Primary Endpoint in First-Ever Clinical Study Comparing Drug-Eluting Stents in High-Bleeding Risk (HBR) Patients with One-Month DAPT
DUBLIN and SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) announced today late-breaking clinical data from the Onyx ONE Global Study, representing the first prospective, multi-center, randomized study evaluating clinical outcomes between two drug-eluting stents (DES) in nearly 2,000 high-bleeding risk (HBR) patients with one month of dual antiplatelet therapy […]
Access Vascular Secures New Financing to Accelerate Commercialization
BEDFORD, Mass., Sept. 26, 2019 /PRNewswire/ — Access Vascular, a medical device company developing the next generation of intravenous devices from novel biomaterials designed to minimize the risk of bloodstream infection, catheter thrombosis, and vein trauma, announced $6M in new funding from new and existing investors. With this new round, Access Vascular is poised to […]
BD Announces Leadership Succession Plan
FRANKLIN LAKES, N.J., Sept. 26, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vincent A. Forlenza, chairman and CEO, will retire as CEO on Jan. 28, 2020, following the company’s annual meeting of shareholders. Forlenza will continue on the BD board of directors, serving as […]
FDA Clears Modules of AI-Rad Companion Chest CT From Siemens Healthineers
MALVERN, Pa.–(BUSINESS WIRE)– The U.S. Food and Drug Administration (FDA) has cleared three modules of AI-Rad Companion Chest CT¹, an intelligent software assistant from Siemens Healthineers that brings artificial intelligence (AI) to computed tomography (CT). Representing the first intelligent assistant of the new AI-Rad Companion platform, AI-Rad Companion Chest CT […]
CorMatrix® Cardiovascular, Inc. completes enrollment of adult arm of its FDA early feasibility IDE study for the Cor® TRICUSPID ECM® valve for pediatric and adult patients
ATLANTA, Sept. 26, 2019 /PRNewswire/ — CorMatrix® Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced it has completed enrollment of the adult arm of its FDA early feasibility IDE study for the Cor® TRICUSPID ECM® cardiac valve* for adults with endocarditis and for pediatric patients with congenital heart valve disease. The Cor® TRICUSPID ECM® valve […]
Ancora Heart Announces Positive Safety and Efficacy Data from Study of First-of-Its-Kind Investigational Heart Failure Therapy
SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced results from an interim analysis of heart failure patients treated in the CorCinch FMR study, a U.S. early feasibility study evaluating the safety of the investigational AccuCinch® Ventricular Repair System designed for the […]
United Biologics, Inc. Appoints John Barnhill as Its President and General Manager
SANTA ANA, Calif.–(BUSINESS WIRE)–United Biologics, Inc., a global leader in silicone vasculature, today announced the appointment of John Barnhill as President and General Manager. As President and General Manager, Mr. Barnhill will guide the company’s commercial advancement and innovation strategies, as well as oversee all financial and operations infrastructure to […]
Abiomed Receives FDA PMA Approval for Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed’s (NASDAQ: ABMD) newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for safety and efficacy in the therapy of cardiogenic shock for up to 14 days. Impella 5.5 with SmartAssist is: Minimally invasive, eliminating the need for a […]



